Biocept is a molecular oncology diagnostics company that develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA (ctDNA) from blood and cerebrospinal fluid (CSF). Co. has commercialized its CNSide assays for detecting and characterizing various different carcinomas melanoma. These assays utilize Co.'s dual cellular and ctDNA technology platforms and provide biomarker analysis from a patient's CSF sample. In addition, Co. has introduced molecular testing for SARS-CoV2, the virus responsible for COVID-19, using the RT-PCR method developed by Thermo-Fisher.. We show 30 historical shares outstanding datapoints in our BIOC shares outstanding history coverage, used to compute BIOC market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BIOC market cap history over the course of time is important for investors
interested in comparing BIOC's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BIOC versus a peer is one thing; comparing
BIOC market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BIOC can fluctuate over the course of history.
With this page we aim to empower investors researching BIOC by allowing them to research the BIOC market cap history. |
Free BIOC Email Alerts:
Video: The Importance of Market Cap
